SCHEMBL145280

SCHEMBL145280

CC(C)(C)OC(=O)NCC1CCCN1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.44
DRD2 P14416 3/20 0.40
DRD3 P35462 2/20 0.40
SCN9A Q15858 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
TDP1 Q9NUW8 1/20 0.38
GFER P55789 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CACNA1F O60840 1/20 0.37
KCNA5 P22460 1/20 0.37
SLC6A2 P23975 1/20 0.37
ADRA1A P35348 1/20 0.37
OPRK1 P41145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268688 1.00 EPHX1 (0.44) EPHX1DRD2DRD3SCN9AOPRM1
SCHEMBL79825 1.00 EPHX1 (0.44) EPHX1DRD2DRD3SCN9AOPRM1
Hydrochloric Acid SCHEMBL2417195 0.98 EPHX1 (0.43) EPHX1DRD2DRD3SCN9AOPRM1
Hydrochloric Acid SCHEMBL2422106 0.98 EPHX1 (0.43) EPHX1DRD2DRD3SCN9AOPRM1
SCHEMBL16528516 0.95 EPHX1 (0.47) EPHX1DRD2DRD3SCN9AOPRM1
SCHEMBL487705 0.95 EPHX1 (0.47) EPHX1DRD2DRD3SCN9AOPRM1
SCHEMBL1062309 0.95 EPHX1 (0.47) EPHX1DRD2DRD3SCN9AOPRM1
Formic Acid Methyl Ester SCHEMBL28112828 0.92 EPHX1 (0.39) EPHX1DRD2DRD3SCN9AOPRM1
SCHEMBL1398833 0.89 EPHX1 (0.44) EPHX1DRD2TDP1GFERTSHR
SCHEMBL18992238 0.89 EPHX1 (0.44) EPHX1DRD2TDP1GFERTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739685-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
EP-3761989-B1 IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF GFB ABC LLC (US) 2026-05-13 EP disclosed
US-20250388533-A1 PRODRUGS OF PHENOLIC TRPV1 AGONISTS CONCENTRIC ANALGESICS INC (US) 2025-12-25 US disclosed
US-12466815-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2025-11-11 US disclosed
US-12466834-B2 Imidazodiazepinediones and methods of use thereof GFB (ABC), LLC (US) 2025-11-11 US disclosed
WO-2025008061-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed
CN-112351781-B Imidazodiazepine diketones and methods of use thereof 金翅雀生物公司 2024-07-02 CN disclosed
US-20240150326-A1 CARBOXAMIDE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-05-09 US disclosed
CN-117986272-A Condensed polycyclic compounds, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-05-07 CN disclosed
US-11866426-B2 Benzothiazole compounds and uses thereof INCYTE CORPORATION (US) 2024-01-09 US disclosed
US-20040248886-A1 Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors MERCK SERONO SA (CH) 2004-12-09 US disclosed
US-20040220169-A1 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-11-04 US disclosed
WO-2004092170-A2 TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGON ISTS BIOGEN IDEC MA INC. (US) 2004-10-28 WO disclosed
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-09 US disclosed
WO-2004056784-A1 NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-08 WO disclosed
EP-0539281-B1 Naphthamides, process for their preparation and their application in the therapeutical field INST NAT SANTE RECH MED (FR) 1998-12-30 EP disclosed
US-5498628-A ANTIPSYCHOTIC, PSYCHOSTIMULATORY, ANTIAUTISTIC, ANTIDEPRESSANT AND HYPOTENSIVE AGENTS, PARKINSON'S DISEASE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1996-03-12 US disclosed
EP-0539281-A1 New naphthamides, process for their preparation and their application in the therapeutical field INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1993-04-28 EP disclosed
US-5189046-A Antiinflammatory agents, anticonvulsants NOVA PHARMACEUTICAL CORPORATION (US) 1993-02-23 US disclosed
WO-1992003415-A1 PROTEIN KINASE C MODULATORS NOVA PHARMACEUTICAL CORPORATION (US) 1992-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248886-A1 Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors MAPK1, MAPK3, MAP3K2 EPHX1 3928/4885DRD2 3041/4885DRD3 2839/4885
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions F11, F12, F2 EPHX1 1415/4885DRD2 2845/4885DRD3 1754/4885
US-20250388533-A1 PRODRUGS OF PHENOLIC TRPV1 AGONISTS TRPV1, TRPV3, TRPV4 EPHX1 2273/4885DRD2 315/4885DRD3 273/4885
US-20240150326-A1 CARBOXAMIDE COMPOUNDS AND USES THEREOF PCK1, PHKG2, PHKG1 EPHX1 1708/4885DRD2 4842/4885DRD3 4823/4885
US-11866426-B2 Benzothiazole compounds and uses thereof PDXK, PCK1, HIPK1 EPHX1 1416/4885DRD2 4880/4885DRD3 4860/4885
US-20040220169-A1 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions F12, F11, F2 EPHX1 1218/4885DRD2 3891/4885DRD3 3450/4885
US-12466815-B2 Carboxamide compounds and uses thereof PCK1, PHKG2, PHKG1 EPHX1 1708/4885DRD2 4842/4885DRD3 4823/4885
US-12466834-B2 Imidazodiazepinediones and methods of use thereof REN, ATP6V1B1, GLS EPHX1 832/4885DRD2 173/4885DRD3 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.